The lawsuit, pending in the United States District Court for the District of Connecticut, centers on the period between April 16, 2025, and May 4, 2026. Investors represented by Kahn Swick & Foti, LLC allege that GeneDx executives failed to disclose critical information concerning the company's operational health. The legal action points to the May 4, 2026, disclosure of a $31.2 million impairment loss tied to Fabric Genomics, an AI-driven firm previously marketed as a key driver for long-term revenue growth.
In section Releases
GeneDx Investors Face Deadline in Securities Fraud Class Action
A 49% collapse in GeneDx Holdings stock has triggered a class action lawsuit, with investors now facing an August 3, 2026, deadline to seek lead plaintiff status. The litigation follows allegations that the company misled shareholders regarding the financial performance of its acquisition of Fabric Genomics.
Following the revelation of missed revenue estimates for exome and genome lines and a downward revision of annual guidance to between $475 and $490 million, the company’s share price dropped by $33.42. Investors who incurred losses during the class period may contact managing partner Lewis Kahn to discuss potential recovery options. The case, Basma v. GeneDx Holdings Corp., highlights the risks associated with the integration of acquired technologies that fail to meet projected financial expectations.
Comments (0)
No comments yet. Be the first!